gemcitabine has been researched along with tanespimycin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arlander, SJ; Eapen, AK; Karnitz, LM; McDonald, RJ; Toft, DO; Vroman, BT | 1 |
| Batzel, G; Erlichman, C; Felten, S; Haluska, P; Hubbard, J; Ivy, SP; Qin, R; Stensgard, BA; Ten Eyck, C; Toft, DO | 1 |
| Camoriano, JK; Colon-Otero, G; Erlichman, C; Glaser, G; Haluska, P; Hendrickson, AE; Ivy, SP; Karnitz, LM; Kaufmann, SH; Oberg, AL; Peethambaram, PP | 1 |
| Erlichman, C; Foster, NR; Kim, GP; McWilliams, RR; Pedersen, KS; Wang-Gillam, A | 1 |
| Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U | 1 |
3 trial(s) available for gemcitabine and tanespimycin
| Article | Year |
|---|---|
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Cisplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Neoplasms; Protein Serine-Threonine Kinases; Treatment Outcome | 2011 |
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate | 2012 |
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Deoxycytidine; Female; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2015 |
2 other study(ies) available for gemcitabine and tanespimycin
| Article | Year |
|---|---|
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
Topics: Antimetabolites, Antineoplastic; Benzoquinones; cdc25 Phosphatases; Cell Line; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Lactams, Macrocyclic; Precipitin Tests; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Rifabutin; S Phase; Signal Transduction; Time Factors | 2003 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence | 2017 |